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ABSTRACT 
 
Characterization of Mycosin family proteases, Novel Drug Targets of Mycobacterium 
tuberculosis (April 2007) 
 
Hilary J. Baird 
Department of Biochemistry 
Texas A&M University 
 
Research Advisor: Dr. James C. Sacchettini 
Department of Biochemistry 
 
Tuberculosis is the world’s leading cause of death by infectious disease.  Antibiotic 
resistance and HIV co-infection is increasing at an alarming rate.  Mycosins-1-5 are 
subtilisin-like serine proteases within the periplasmic space of the tuberculosis bacterial 
cell.  However, to date, Mycosin-1 is thought to be the most interesting because it is only 
expressed after TB infection and is thought to be essential to its virulence.  The role of 
Mycosins-2-4 is not yet known.  These factors make Mycosin-1 a novel drug target.  
This study aims to clone and characterize Mycosin-1 for further investigation as a drug 
target.  The mycosin-1 and mycosin-2 genes were successfully cloned for later use in 
expression studies.  Mycosin-2 has been included in the cloning process because of the 
conservation of the Mycosins’ active sites.  The most potent inhibitor will be able to 
bind all five Mycosins.  Several sequence alignments have also been included to help 
characterize the Mycosin-1 protein.  The evidence suggests that Mycosin-1 is a typical 
subtilisin-like protease, allowing the characterization of the protein.  A homology model 
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has been built to gain further insight into the protein and for later use in virtual inhibitor 
screening.    
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CHAPTER I 
INTRODUCTION 
 
Mycobacterium tuberculosis is the single leading cause of death by infectious disease in 
the world.  The WHO (World Health Organization) reported that in 2004, 1.7 million 
deaths were a result of Mtb infections (1).  Although the rate of infection is decreasing in 
developed areas of the world, it is increasing by 0.6% per year on a global scale (1).  The 
infection is spread through the air and individuals with active, untreated, infections will 
on average infect 10-15 people per year.  It is also estimated that only half of Mtb cases 
were reported by health-care systems in 2004 and just 82% of these finished treatment 
(2).  Mtb has the ability to survive for long periods in the host mandating extended drug 
treatments and thus resulting in low compliance. A recent article also claimed that “one-
third of the world’s population is infected with TB, and hundreds of thousands of 
children will become TB orphans this year” (3).  
 
Mtb is reaching an alarming magnitude in underdeveloped regions of the world such as 
Africa.  As the number of people with AIDS increase, so does the rate of Mtb.  In fact, it 
is the leading cause of death of individuals who have AIDS.  Also, AIDS patients are 50 
times more likely to develop Mtb than those who are HIV negative.  Approximately one 
third of people with HIV are co-infected with Mtb and 90% of those will die within 
months of the Mtb infection without treatment (4).   
_______________ 
This thesis follows the style of Journal of Biological Chemistry. 
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Fig. 1. Incidences of reported Tuberculosis in 2003.  (1) 
 
 
 
Drug Resistance 
In the past years, strains of drug resistant Mtb have become prevalent.  In fact, resistance 
is so wide spread that it is now being classified as multi-drug resistant (MDR-TB) and 
extreme-drug resistant (XDR-TB).  Indeed, strains of Mtb have even evolved resistance 
to all major anti-TB drugs available.  The infection can still be cured with extensive 
chemotherapy, however a need for a more readily available treatment is evident.  Little 
is known about the actual mechanism that controls the interactions between the host and 
Mtb and even less is known on how such interactions affect the life cycle of the host or 
the pathogen. Therefore, novel targets for new drug treatment are needed.   
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Mycosin-1 
The mycosins are a family of 5 genes present in Mtb.   They are subtilisin-like serine 
proteases with a highly conserved catalytic triad (Asp, His, Ser) (5).  They each have a 
C-terminal transmembrane region and an N-terminal signal peptide, represented in figure 
2.  Mycosin-1 (MycP1), Rv3883c, is an extra cellular protein that is membrane and cell 
wall associated.  It is most likely subject to cleavage of the signal peptide region 
following secretion from the cell (5).  MycP1 is expressed after infection of Mtb, making 
it a potential drug target.  
 
 
Fig. 2. A representation of the MycP1 protein.  This figure denotes the active site residues, the signal 
sequence and the transmembrane region. 
 
 
The Mycosin proteins are highly conserved, shown by the sequence alignment in figure 
3.  The active site residues are denoted using orange stars.  Most importantly, the active 
sites of the proteins are conserved.  This is significant because an inhibitor molecule that 
binds to one Mycosin will have a higher probability to inhibit all of them, allowing all 
five genes to be targeted for drug design.   
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Fig. 3. Sequence alignment of the five mycosin proteins.   Sequence produced using Clustalw, version 
3.2 and Textshade (6) (7). 
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In Mtb, there are eight regions of difference (termed RD1-8) between the genome of the 
virulent and non-virulent strains (8).  RD1 is known to contain the esxA/esxB operon 
which encodes two predominant Mtb antigens, ESAT-6 and CFP-10.  Several of the 
genes surrounding the esxA/esxB operon were deleted from Mycobacterium bovis on the 
path to obtaining the attenuated M. bovis BCG vaccine strain (8).  An alternate protein 
secretion system, called the Snm (secretion in mycobacteria) pathway, is encoded in 
Mtb.  This system includes RD1 as well as several surrounding genes that are conserved 
to the region.  The proteins encoded by these surrounding genes are thought to aid in the 
secretion of the ESAT-6 and AFP-10 antigens (8).  The most notable of these is 
Mycosin-1 (MycP1), because it was found to be required for the functioning of the Snm 
pathway.  Because of MycP1’s location in the periplasm, it is hypothesized that MycP1 
acts as a regulator of Snm secretion, either breaking down an Snm inhibitor or activating 
an Snm protein (8). 
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CHAPTER II 
METHODS 
 
Truncation and Primer Design 
Mycosin-1 
 
MycP1 has an N-terminal signal sequence and C-terminal transmembrane region as 
shown in figure 3. Previous attempts to express the full-length protein yielded insoluble 
protein products (Jim Sacchettini, Personal communication). Generally, signal peptides 
and transmembrane helices consist of high proportions of hydrophobic residues. 
Removing both these hydrophobic tail regions should greatly enhance the solubility of 
the protein.   The protein was therefore truncated at the 49th and the 417th amino acid 
residue to increase the solubility after expression. The active site residues occur at amino 
acids 101 (Asp), 122 (His), and 336 (Ser); leaving a sufficient number of amino acids 
before the active site residues, making this a safe truncation.    
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Fig. 4. The prediction of transmembrane helices for the mycP1 amino acid sequence.  The  TMHMM 
server was used. The sequence was truncated at amino acid residues 49 and 417 (9). 
  
 
The E. coli vector pET-28b ((Novagen, EMD Biosciences)) was used with the restriction 
enzymes Nhe1 and HindIII.  Two reverse primers were designed; one without a stop 
codon and the other with a stop codon inserted at the end of the truncated mycP1 
sequence.  This allowed an N-terminal His-tag and both N- and C-terminal His-tags to 
be inserted onto the protein sequence.  The primer sequences used were: 
Forward (using Nhe1): 5’AGCCTAGCTAGCGATCAGCCTACCGAACAGCG 3’ 
Reverse, no stop (using HindIII): 
5’AGCCTAAAGCTTGCGACGATCGGGACCCGGCTC 3’ 
Reverse, stop (using HindIII): 
5’AGCCTAAAGCTTTCAGCGACGATCGGGACCCGGCTC 3’ 
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Mycosin-2 
Due to the conservation among the mycosins, cloning of mycosin-2 (mycP2), Rv3886c, 
was also tried.  This protein also has hydrophobic rich N-terminal signal sequence and 
C-terminal transmembrane region, as seen in figure 4.  The protein was truncated at the 
56th and 507th amino acids thus removing both the hydrophobic regions.    
 
 
Fig. 5. The prediction of transmembrane helices for the mycP2 amino acid sequence.   The protein 
was truncated at amino acids 56 and 507.  The active site residues occur at amino acids 103 (Asp), 
133(His), and 435(Ser).  The small hydrophobic region occurring between amino acids 425 and 450 could 
not be truncated without interfering with the active site of the protein.  However, it should not interfere 
with expression and the truncation made is considered safe (9). 
 
 
 
The primers for mycP2 were designed to allow proteins with N-terminal, C-terminal, 
and both N- and C-terminal His-tags to be produced.  The E. coli vector pET-28b 
(Novagen, EMD Biosciences) was used with the restriction enzymes Nde1 and HindIII 
to produce protein sequences with the N-terminal and the N- and C-terminal His-tags.  
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The E. coli vector pET-30b (Novagen, EMB Biosciences) was used to produce a protein 
sequence with only C-terminal His- tag.  The primers used were: 
Forward (using Nde1): 5’AGCCTACATATGGCGCCGCTCCAACAGCTGCTCCA 3’ 
Reverse no stop (using HindIII): 
5’AGCCTAAACATTCCGGCTCTGTGCACCCGGGGC 3’ 
Reverse stop (using HindIII): 
5’AGCCTAAAGATTTCACCGGCTCTGTGCACCCGGGGC 3’ 
 
Cloning  
The mycP1 and mycP2 gene fragments were amplified using PCR; a FailSafe PCR kit 
(Epicentre Biotechnologies) was used.  An agarose DNA gel was run to check the PCR 
products.  The amplified PCR products were purified using a PCR purification kit 
(Qiagen).  The respective vector and PCR products were double digested using the 
restriction enzymes previously defined.  The outcomes of the double digestions were run 
on an agarose DNA gel to ensure the correct cutting by the restriction enzymes.  The 
mycosin DNA fragments were then ligated with the respective linearized E. coli vector 
and transformed into Novablue E. coli competent cells.  A Rapid DNA Ligation Kit 
(Roche) was used for the ligation.   
 
The Novablue cells were plated onto LB media containing the antibiotic kanamycin (50 
µg/ml) and allowed to incubate overnight at 37°C.  A single colony from the plate was 
transferred into liquid LB media, containing kanamycin, and grown at 37°C for several 
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hours.  A plasmid miniprep kit (Qiagen) was used to extract the E. coli vectors 
containing the cloned mycosin gene.  The mycP1 and mycP2 plasmids were then sent for 
DNA sequencing to ensure the correct inserts. 
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CHAPTER III 
RESULTS 
 
Cloning 
The DNA encoding hydrophobic regions of mycP1 and mycP2 were truncated to 
promote soluble expression of the proteins in E. coli cells.  After truncation, mycP1 was 
approximately 1100 base pairs and mycP2 was approximately 1500 base pairs.  MycP1 
and mycP2 genes were successfully cloned using Mtb genomic DNA (H37Rv strain).  
The primer sequences for N-terminal His-tags were used for the PCR amplification.  The 
PCR products were run on a DNA agarose gel to ensure the best buffer conditions for 
producing DNA fragment were used, as seen in figure 5.  Although products were seen 
in conditions D, G, and K, only conditions D and G were used for mycP1 and mycP2 
respectively.  The DNA concentrations of these samples were estimated to be 82.5ng/µl 
for mycP1 and 57.5ng/µl for mycP2.  
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Fig. 6. PCR products of mycP1 and mycP2.  Left:  PCR products of mycP2, the darkest band 
corresponds to buffer condition G.  Right:  PCR products of mycP1, the darkest band corresponds to 
buffer condition D.   
 
 
 
However, several additional PCR reactions were run to produce more samples.  A 
Phusion High-fidelity PCR kit (New England Bio Labs) was used with two separate 
reaction mixes to optimize the insert amplification produced.  The agarose gel of the 
PCR products can be seen in figure 6.  Reaction mix one, using the Failsafe buffer 
condition G, only produces a significant amount of mycP2 DNA fragments.  The 
reaction mix two, using 5x fusion buffer and 10mM dNTP’s, did not produce a 
significant amount of either gene.  A test DNA (1300 bp) was used to ensure the PCR 
reaction worked.   
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Fig. 7. PCR products using Phusion High-fidelity PCR kit.  A test was used both reaction mixes to 
ensure the efficiency of the PCR.  The mycP1 gene was not significantly produced in either mix, while 
mix one produced a significant amount of mycP2.  The low band in the mycP2, reaction mix two lane is 
most likely the primers used in the reaction. 
 
 
 
The pET-28b vector and DNA fragments were double digested with restriction enzymes.  
DNA fragments from two PCR’s were used for each gene to ensure the effectiveness of 
the double digestion.  The NEB buffer 2 and BSA were used for maximum efficiency.  
The section cut out of the pET-28b vector was too large, greater than 100bp, to be 
removed using the PCR purification kit.  Therefore, the linearized vector had to be 
purified by running it onto an agarose gel and then gel purifying the vector band by 
excising it from the gel.  The linearized vector was approximately 5200 bp and estimated 
to be 95 ng/µl. 
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The two samples of mycP1 and mycP2 genes were initially ligated with the linearized 
vector using a 1:3 (vector to insert) ratio.  However, after transforming the ligation 
products into Novablue (a non-expression strain of E. coli), no colonies were produced 
on the LB plates.  This could have been due to a failed ligation or failed transformation.  
The ligation reactions were repeated using the ratios 1:3 as well as 1:4 (vector to insert).  
The transformation into Novablue cells was successful with both ratios.  The colonies 
produced using the ratio 1:3 were chosen for further experiment.   
 
The Novablue cells were grown in LB media and harvested to extract the plasmids 
containing the mycP1 and mycP2 genes.  The extracted plasmids were sent for DNA 
sequencing as well as tested for the presence of insert.  A double digestion using the 
original restriction enzymes was run for each of the plasmids.  The agarose gel can be 
seen in figure 8.  Samples corresponding to the two separate PCR are shown.  The 
double digestion of the mycP2 sample shown in lane three revealed that the ligation 
reaction failed.  The plasmid must have recircularized without the mycP2 gene insert.  
This is proven by the absence of any addition bands in the lane as well as the size of the 
digested plasmid.  From the figure 8 it is clearly evident that the double digestion was 
successful as the vector backbone bands are all of same expected size. 
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Fig. 8. Double digestion verification of the gene inserts. 
 
 
 
The gene inserts were also verified using PCR.  The reaction mix one was used because 
only it produced visible bands for both of the genes.   Instead of using the genomic DNA 
of Mtb as a template, the plasmids extracted from Novablue cells were used.  The results 
of the PCR verification are shown in figure 9.  The failure of the mycP2 gene to insert 
into the vector is further proven.  No products can be seen from that reaction.  This is 
most likely due to the absence of the gene insert in the plasmid used as the template. 
  16 
 
Fig. 9. PCR verification of the gene inserts. 
 
 
 
Mycosin Homologs  
MycP1 is a subtilisin-like serine protease that is thought to be essential to the life cycle 
of Mtb.  Subtilisins can be found in viruses, bacteria, as well as eukaryotes.  For this 
reason, the MycP1 protein sequence was BLASTed against the non-redundant protein 
sequence database to identify homologs in other species.  The results showed that the 
majority of homologs are contained in bacteria.  Although similar sequences were found 
mainly in Mycobacterium, some were identified in Nocardia, Bacillus, and 
Corynebacterium as well as others.  Table 1 identifies a sampling of the species found to 
contain homologs to mycP1.   
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Species PDB/Reference 
Number 
Characteristics Identity 
Mycobacterium 
leprae  
 
NP_301157.1 
 
Probable secreted 
protease 
354/446 (79%) 
 
Mycobacterium 
smegmatis 
YP_884499 Membrane-
anchored mycosin 
mycp1 
321/443 (72%) 
 
Nocardia farcinica YP_117037 Putative protease 198/436 (45%) 
 
Saccharopolyspor
a erythraea 
YP_001108883 Putative serine 
protease 
165/419 (39%) 
 
Corynebacterium 
glutamicum 
BAB97968 Hypothetical 
protein 
 
138/390 (35%) 
 
Streptomyces 
avermitilis 
NP_823716 Serine protease 118/362 (32%) 
 
Bacillus sp. ZP_01168843 Alkaline serine 
protease, subtilase 
104/346 (30%) 
 
Erythrobacter 
litoralis 
YP_458816 Predicted 
subtilase 
108/328 (32%) 
 
Lyngbya sp. ZP_01619435 Peptidase S8 and 
S53, subtilisin, 
kexin 
104/342 (30%) 
 
Bacillus sp. 
 
1DBI Thermostable 
Serine protease 
90/268 (33%) 
 
Table 1. A sampling of the species found to contain homologs of the mycP1 protein.  The search 
produced several hits in mycobacterium species and only few of them are shown here for clarity (10). 
 
 
A phylogenetic tree, figure 10, was constructed to examine the evolutionary distance 
between the bacterial homologs.  The tree was constructed using an implicit alignment 
between the database sequences.  This is based on the alignment of the sequences with 
the MycP1 protein.  
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Fig. 10. Phylogenetic tree showing the divergence of mycP1 homologs.  The protein labeled unknown 
in yellow highlighting is the submitted mycP1 sequence.  The closest match the program made was, in 
fact, the mycP1 protein in Mtb, seen directly next to the submitted sequence.  Key: high GC Gram+: green, 
eubacteria: brown, a-proteobacteria: blue, cyanobacteria: magenta.  The tree was produced using BLAST 
distance tree results and a pairwise alignment (10). 
 
 
 
The MycP1 protein was also found to have a homolog in Homo sapiens.  The 
conservation in species ranging from bacteria to humans suggests that MycP1 may play 
an important role in the life cycle.  Although the identity between human and Mtb 
proteins is low, this result is significant for drug design.  It is essential that an inhibitor 
designed to treat an infection in humans does not interact with, and therefore, potentially 
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inactivate human proteins.  Even though the infection may be successfully treated, the 
inhibitor could also cause sever and unexpected effects in a person.   
 
The similarity of the two proteins can make inhibitor design for the MycP1 protein 
difficult because of the potential binding to the human homolog.  It is possible, however, 
to specifically design the inhibitor only for the Mycobacterium species because the 
conservation between the two proteins is low.  Figure 11 shows the sequence alignment 
of the MycP1 protein and the human homolog.  It can be seen that the active site of the 
MycP1 protein (denoted by orange stars) is not conserved in the human homolog, even 
though it is also a subtilisin/kexin-like protease.  This will enable the designing of an 
inhibitor that will only fit the MycP1 active site.   
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Fig. 11. The sequence alignment of MycP1 and a human homolog.  Orange stars denote the active site 
of the MycP1 protein.  The active site is not conserved even though the human homolog is a 
subtilisin/kexin-like protease as well (6) (7). 
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Subtilisins 
Subtilisins are proteolytic enzymes that were originally identified in Bacillus subtilis, 
belonging to the peptidase S8 family.  It is the largest class of serine proteases so far 
identified.  A catalytic triad containing the amino acids serine, aspartic acid and 
histadine characterizes them.  A three-element fingerprint involving the motifs 
surrounding the active residues identifies these proteins.  Table 2 shows the fingerprint 
results of MycP1, subtilisin being the top and only significant match.   
 
Fingerprint # of 
Motifs 
IdScore PfScore Pvalue Sequence Len Low Pos high 
SUBTILISIN 1 of 3 38.89 341 5.11e-
06 
GAGVTVAVI 
DTGVDASPRVP 
20 23 473 81 
SUBTILISIN 2 of 3 43.83 269 2.64e-
03 
DCDAHGTLT 
ASIIA 
14 58 552 117 
SUBTILISIN 3 of 3 49.11 382 8.84e-
07 
AGTSFAAAYV 
SGLAALL 
17 212 864 329 
Table 2.  Fingerprint results of the MycP1 protein sequence.  The motifs involved include: 1- the 
“region encoded by PROSITE pattern SUBTILASE_ASP (PS00136), which contains the active Asp; 
motif 2 spans the region encoded by PROSITE pattern SUBTILASE_HIS (PS00137), which contains the 
active His; and motif 3 includes the region encoded by PROSITE pattern SUBTILASE_SER (PS00138), 
which contains the active Ser.” (11) (12) 
 
 
 
The MycP1 homologs identified are serine proteases with most of them belonging to the 
subtilisin family.  The conservation of motifs throughout these proteins was identified 
and can be seen in figure 12.  The motifs within the MycP1 protein are highly conserved 
along the other subtilisin proteases.  For this reason, it can be inferred that MycP1 will 
follow the general characteristics of the subtilisin family.   
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                       10        20        30        40        50        60        70        80 
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
1DBI_A       13 YGPQNTYTDYaWDVtKGSSGQEIAVIDTGVDYTHPDLDGKVIKGYDFVDNDY-DPM---DLNNHGTHVAGIAAAETNNAT 88 
MycP1_TB     65 WSNTYLGVADaHKf-ATGAGVTVAVIDTGVDASP---RVPAEPGGDFVD-QA-GNGl-sDCDAHGTLTASIIAGRPAPTD 137 
gi 130964   154 IDQRNLPLDNnYSAnFDGTGVTAYVIDTGVNNAHVEFGGRSVSGYDFVDNDAda----sDCNGHGTHVAGTIGGS----- 224 
gi 114081   140 IDQRDLPLSNsYTYtATGRGVNVYVIDTGIRTTHREFGGRARVGYDALGGNGq------DCNGHGTHVAGTIGGV----- 208 
gi 124932    24 RGVEMIQAPAvWNQ-TRGRGVKVAVLDTGCDADHPDLKARIIGGrNFTDDDEgDPeifkDYNGHGTHVAGTIAAT-ENEN 101 
1THM         13 YGPQKIQAPQaWDI-AEGSGAKIAIVDTGVQSNHPDLAGKVVGGWDFVDNDStp----qNGNGHGTHCAGIAAAVTNNST 87 
gi 549004   112 YGISQIKAPAlHSQgYTGSNVKVAVIDSGIDSSHPDLNVRgg--asFVPSETn-PYq--DGSSHGTHVAGTIAAL-NNSI 185 
gi 12643279  98 WGISFINTQQaHNRgIFGNGARVAVLDTGI-ASHPDLRIAG----GASFISSeps--yhDNNGHGTHVAGTIAAL-NNSI 169 
1AH2          6 WGISRVQAPAaHNRgLTGSGVKVAVLDTGI-STHPDLNIRgg--asFVPGEPst----qDGNGHGTHVAGTIAAL-NNSI 77 
1MEE_A        6 YGISQIKAPAlHSQgYTGSNVKVAVIDSGIDSSHPDLNVRg--gASFVPSETn-PYq--DGSSHGTHVAGTIAAL-NNSI 79 
                        90       100       110       120       130       140       150       160 
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
1DBI_A       89 GIAGMAPNTRILAVR----ALDRNGS-------------GTLsDIADAIIYAAd--sGAEVINLS------LGCDchttT 143 
Mycp1_TB    138 GFVGVAPDARLLSLRqtseAFEPVGSqanpndpnatpaaGSIrSLARAVVHAAn--lGVGVINISeaacykVSRPidetS 215 
gi 130964   225 -LYGVAKNVNLVGVR----VLSCSGS-------------GSTsGVIAGVDWVAanasGPSVANMS------LGggq-svA 279 
gi 114081   209 -TYGVAKAVNLYAVR----VLDCNGS-------------GSTsGVIAGVDWVTrnhrRPAVANMS------LGggv-stA 263 
gi 124932   102 GVVGVAPEADLLIIK----VLNKQGS-------------GQYdWIIQGIYYAIe--qKVDIISMS------LGGpedvpe 156 
1THM         88 GIAGTAPKASILAVR----VLDNSGS-------------GTWtAVANGITYAAd--qGAKVISLS------LGGTvgnsg 142 
gi 549004   186 GVLGVAPSASLYAVK----VLDSTGS-------------GQYsWIINGIEWAIs--nNMDVINMS------LGGPtgstA 240 
gi 12643279 170 GVLGVAPSADLYAVK----VLDRNGS-------------GSlasVAQGIEWAIn--nNMHIINMS------LGSTsgssT 224 
1AH2         78 GVLGVAPNAELYAVK----VLGASGS-------------GSvsSIAQGLEWAGn--nGMHVANLS------LGSpspsaT 132 
1MEE_A       80 GVLGVAPSASLYAVK----VLDSTGS-------------GqysWIINGIEWAIs--nNMDVINMS------LGGPtgstA 134 
                       170       180       190       200       210       220       230       240 
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
1DBI_A      144 LENAVNyAWNKGSVVVAAAGNNGSSTTfEpa------------------------sYE--NVIAVGAVDQYDRLASFSNY 197 
Mycp1_TB    216 LGASIDyAVNVKGVVVVVAAGNTGGDCvQnpapdpstpgdprgwnnvqtvvtpawyAP--LVLSVGGIGQTGMPSSFsmh 293 
gi 130964   280 LDSAVQsAVQSGVSFMLAAGNSNADACnYsp-----------------------arVA--TGVTVGSTTSTDARSSFSNW 334 
gi 114081   264 LDNAVKnSIAAGVVYAVAAGNDNANACnYsp-----------------------arVA--EALTVGATTSSDARASFSNY 318 
gi 124932   157 LHEAVKkAVASQILVMCAAGNEGDGDDrTdel---------------------gypGCynEVISVGAINFDRHASEFSNS 215 
1THM        143 LQQAVNyAWNKGSVVVAAAGNAGNTAPnYpa------------------------yYS--NAIAVASTDQNDNKSSFSTY 196 
gi 549004   241 LKTVVDkAVSSGIVVAAAAGNEGSSGStStvgy--------------------pakYP--STIAVGAVNSSNQRASFSSV 298 
gi 12643279 225 LELAVNrANNAGILLVGAAGNTGRQGVnYpa------------------------rYS--GVMAVAAVDQNGQRASFSTY 278 
1AH2        133 LEQAVNsATSRGVLVVAASGNSGAGSIsYpa------------------------rYA--NAMAVGATDQNNNRASFSQY 186 
1MEE_A      135 LKTVVDkAVSSGIVVAAAAGNEGSSGS-Tstvg-------------------ypakYP--STIAVGAVNSANQRASFSSA 192 
                       250       260       270       280       290       300       310       320 
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
1DBI_A      198 GTWVDVVAPGVDIVST--ITG---NRYAY------MSGTSMASPHVAGLAALLASQG-----R--NNIEIRQAIEQTADK 259 
Mycp1_TB    294 GPWVDVAAPAENIVALg-DTGepvNALQGregpvpIAGTSFAAAYVSGLAALLRQRF-----PdlTPAQIIHRITATArh 367 
gi 130964   335 GSCVDVFAPGSQIKSA--WYD---GGYKT------ISGTSMATPHVAGVAALYLQENssvspS--QVEALIVSRASTGKV 401 
gi 114081   319 GSCVDLFAPGASIPSAwyTSD---TATQT------LNGTSMATPHVAGVAALYLEQNpsat-pasvASAILNGATTGRLS 388 
gi 124932   216 NNEVDLVAPGEDILST--VPG---GKYAT------FSGTSMATPHVAGALALIKQLAnasferdlTEPELYAQLIKRTIP 284 
1THM        197 GSWVDVAAPGSSIYST--YPT---STYAS------LSGTSMATPHVAGVAGLLASQG-----R--SASNIRAAIENTADK 258 
gi 549004   299 GSELDVMAPGVSIQST--LPG---GTYGA------YNGTSMATPHVAGAAALILSKHptwtna-----qvrdrlESTATY 362 
gi 12643279 279 GPEIEISAPGVNVNST--YTG---NRYVS------LSGTSMATPHVAGVAALVKSRYps-----ytNNQIRQRINQTATY 342 
1AH2        187 GAGLDIVAPGVNVQST--YPG---STYAS------LNGTSMATPHVAGAAALVKQKNpsws-----nvqIRNHLKNTATS 250 
1MEE_A      193 GSELDVMAPGVSIQSTl--PG---GTYGA------YNGTSMATPHVAGAAALILSKHp---tW--TNAQVRDRLESTATY 256 
                       330 
                ....*....|... 
1DBI_A      260 ISGTGT--YFKYG 270 
Mycp1_TB    368 pgggvddlvgagv 380 
gi 130964   402 TDTRGSvnKLLYS 414 
gi 114081   389 GIGSGSpnRLLYS 401 
gi 124932   285 LGN--SpkMEGNG 295 
1THM        259 ISGTGT--YWAKG 269 
gi 549004   363 LGNs---fYYGKG 372 
gi 12643279 343 LG---SpsLYGNG 352 
1AH2        251 LG---StnLYGSG 260 
1MEE_A      257 LG---SsfYYGKG 266 
 
Fig. 12. The motif alignment of MycP1 with other subtilisin proteins.  The sequence alignment is 
produced by the CDD server (13). 
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Secondary Structure Prediction of MycP1 
 
 
 
 
Fig. 13. Secondary Structure prediction of MycP1.  This prediction was created using the PredictProtein 
server.  The results shown are PHD predictions (14). 
 
 
The predicted secondary structure, figure 13, of MycP1 shows an approximately even 
mix of beta-sheets and helixes.  However, the majority of the structure is shown to be 
loops.  This is consistent with the homology model presented in the following section. 
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Homology Modeling 
Homology modeling is the process of predicting the three dimensional structure of a 
protein.  This is accomplished by identifying a known crystal structure of a similar 
protein.  Protein structures are more conserved than protein sequences, making this a 
significant tool in characterizing proteins.  However, the quality of the model will 
depend on the quality of the sequence alignment and template structure.  Bacillus Ak.1 
protease (PDB ID 1DBI) was identified as the most accurate template for MycP1 with 
41% homology (110/268 AA.).  There are other more similar proteins to the MycP1 
protein, although there are no known structures for the use as a template.  The alignment 
of the two proteins can be seen in figure 14 and most importantly, the active site is 
conserved.  The human homolog identified in figure 11 does not have a conserved active 
site with the bacterial mycosin proteins.  This is significant because it will allow an 
inhibitor to be designed that will only fit into the bacterial mycosin active site, 
essentially not inhibiting the human homolog.   
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Fig. 14. The sequence alignment of Bacillus Ak.1 and MycP1.  Orange stars denote the active site 
residues (6) (7). 
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Fig. 15. Homology model of mycP1 generated using Swiss Molder.  (15) 
 
 
 
The homology model was built using the Swiss homology model sever and the 
MODELLER6.0 program and is seen in figure 15.  This model shows the active site of 
the putative MycP1 protein with an inhibitor docked in it.  Applying the information 
known about the Bacillus Ak.1 protease and subtilisins in general to MycP1, the active 
site can be characterized.  Most subtilisins contain the catalytic triad on the C-terminal 
end of a core β-sheet (16).  The active site cleft is most likely located along the surface 
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of the molecule.  Here, two loops generally join two strand/helix pairs in subtilisins (16).  
In all known crystal structures of subtilisin proteins, calcium-binding sites have been 
identified and are thought to contribute to the stability of the proteins.  However, the 
number of ions and specificity varies between families of subtilisins.  The Bacillus Ak.1 
protease contains three calcium ions and one sodium ion.  The last binding site 
containing the sodium ion is thought to be highly interchangeable with a calcium ion in 
the Bacillus Ak.1 protease (16).  
 
 
Fig 16. Surface representation of the binding Pocket of mycP1 homology modeling.  The putative 
inhibitor binding packet of mycP1 docked with TCA (a serine protease inhibitor).  Blue: Positively 
charged residues, Red: Negatively charged residues   
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Figure 16 shows a closer look at the binding pocket of the homology model.  The first 
step for docking is to define the possible ligand binding sites (figure 16).  The serine 
protease inhibitor TCA was docked into the binding cleft of the MycP1 model.  The 
catalytic residues Asp90, His121 and Ser332 were used as the anchor residues for this 
docking.  This predicted binding pocket could be used in the virtual docking by 
screening more than 2 million ZINC small molecule compounds from the 
MODELLER6.0 database. 
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
1. Mycobacterium tuberculosis contains all five mycosin proteins.  However, to 
date, MycP1 is thought to be the most significant of the five because it is 
expressed during infection.  The expression points of the other four mycosin 
proteins are not really known at this time.  They are all subtilisin like serine 
proteases and have highly conserved active sites, as shown in figure 3.  This 
enables the characterization of MycP1 to be applied to all five Mtb mycosins.   
 
2.  Drug design aims to propose an inhibitor that will enter and bind tightly to the 
target’s active site.  This will prevent the target’s substrate from binding and 
therefore being processed.  It is important to ensure that the target’s affinity for 
the inhibitor is much greater than its affinity for the substrate.  If the target does 
not bind the inhibitor tightly, it will possibly be dislodged temporarily, allowing 
the substrate to enter and be processed.  Although, this processing would be 
greatly reduced, it would lower the effectiveness of the inhibitor as a potential 
treatment.   
 
 The essentiality of proteases to the survival of organisms makes them attractive 
drug targets.  Proteases are a super family of enzymes that act by hydrolyzing 
peptide bonds in other proteins.  They make up approximately 1-5% of an 
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organism’s gene content.  Proteases are essential to the normal functioning of 
cells because they perform a number of post-translational cleavages.  Many 
proteins will not reach their active form if not processed by a protease.  This will 
inevitably disrupt normal functioning and cause “junk” proteins to build up in the 
cell.  Depending on the essentiality of the specific protease function, the cell will 
then die.  Effectively inhibiting the function of an essential protease is a novel 
way of affecting several proteins at once.  These unprocessed, non-functional 
proteins will disrupt the cell’s life cycle at targeted places, effectively treating an 
infection. 
 
3. The conservation of the active sites among the five mycosin proteins increases 
the interest in MycP1 as a drug target.  The most potent inhibitor will, 
presumably, bind to all five mycosin proteins, inactivating them.  This will 
enable a multi-positional attack on the infection.  However, to test this, the 
mycP2 gene has also been cloned for use in expression.  MycP2 will be used to 
test inhibitors along side MycP1 to see the actual activity. 
 
4. The homology model generated for MycP1 can be used as a tentative receptor 
model in an in silico virtual screening using a small molecule database.  The 
database will fit over two million possible inhibitors to the active site of the 
homology model.  The top thousand hits from this virtual screening can then be 
used to test the actual activity of the protein.  It is absolutely essential to test all 
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potential inhibitor with the purified mycosin protein.  The homology model is 
only an estimation of the structure of MycP1.  The actual structure will differ 
from this model, potentially changing the binding of an inhibitor drastically.  
Although no homology modeling of MycP2 will be done virtually, the active 
protein will be tested along side MycP1 to compare the inhibitor binding.     
 
5. The expressed Mycp1 protein can be used in two ways: 
a. It is important to test the MycP1 protein with potential inhibitors using an 
activity assay.  This will test the ability of MycP1 to cleave the peptide 
substrates in the presence of inhibitors.  Para-nitro annelid incorporated 
short peptide fragments can be used as substrates.  When MycP1 cleaves 
the peptide, the para-nitro annelid will be release into the solution.  This 
free para-nitro annelid can be detected using a spectrophotometer.  The 
most ideal inhibitor will prevent MycP1 from cleaving the peptide and 
therefore result in a low absorbance in the spectrophotometer.   
b. Crystallization of the MycP1 protein will allow the three dimensional 
structure to be solved.  The MycP1 crystal will be shot with an x-ray 
beam, creating a diffraction pattern.  Using computer analysis, the three 
dimensional structure will be solved.  This will enable us to examine the 
actual active site of the MycP1 protein.  Virtually, inhibitors can be 
docked to determine the best candidates. 
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The MycP1 protein can also be co-crystallized with potential inhibitors.  
Soaking MycP1 crystals in inhibitor solutions will allow the inhibitor to 
enter and bind to the protein.  The soaked crystal can then be shot with an 
x-ray beam.  The inhibitor will show up in the diffraction pattern, 
demonstrating the interaction with the active site of the protein.  With this 
information, the inhibitor can be virtually modified to optimize binding.   
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